Skip to content
Storytelling Co – Lifestyle
Author:
SOTIO Biotech B.V.
European Patent Office Confirms Patent Protection for SOT201, SOTIO’s Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity
July 21, 2026
FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer
July 14, 2026
SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma
June 3, 2026